The Efficacy and Safety of Subcutaneous Immunotherapy in Mite-Sensitized Subjects With Asthma: A Meta-Analysis.

BACKGROUND: Subcutaneous immunotherapy (SCIT) is widely used in the management of allergic diseases such as allergic asthma. We aimed to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of SCIT in mite-sensitized subjects with asthma. METHODS: Literature from January...

Descripción completa

Detalles Bibliográficos
Publicado en:Respiratory Care Vol. 60; no. 2; pp. 269 - 279
Autores principales: Yanming Lu, Lingyun Xu, Min Xia, Yaqin Li, Lanfang Cao
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Feb2015
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103751055&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 103751055
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00201324
        4GG
      jtl: Respiratory Care
      issn: 00201324
      maglogo: N
    pubinfo:
      dt: Feb2015
      vid: 60
      iid: 2
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        103751055
        100710987
        10.4187/respcare.03399
        NLM25389355
        103751055
      ppf: 269
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: The Efficacy and Safety of Subcutaneous Immunotherapy in Mite-Sensitized Subjects With Asthma: A Meta-Analysis.
      aug:
        au:
          Yanming Lu
          Lingyun Xu
          Min Xia
          Yaqin Li
          Lanfang Cao
        affil: Department of Pediatrics, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
      sug:
        subj:
          Asthma Prevention and Control
          Immunotherapy Methods
          Desensitization, Immunologic Methods
          Mites
          Patient Safety
          Treatment Outcomes
          Human
          Meta Analysis
          Systematic Review
          Embase
          PubMed
          Medline
          Cochrane Library
          Randomized Controlled Trials
          Descriptive Statistics
          Confidence Intervals
          Adolescence
          Child, Preschool
          Child
          Young Adult
          Adult
          Middle Age
          Effect Size
          Data Analysis Software
          Chi Square Test
          Adolescent: 13-18 years
          Child, Preschool: 2-5 years
          Child: 6-12 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
      ab: BACKGROUND: Subcutaneous immunotherapy (SCIT) is widely used in the management of allergic diseases such as allergic asthma. We aimed to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of SCIT in mite-sensitized subjects with asthma. METHODS: Literature from January 1990 to February 2013 on the efficacy and safety of SCIT for mite-sensitized asthma patients was searched in electronic databases, including the Cochrane Library, MEDLINE, Embase, PubMed, China Knowledge Resource Integrated Database, Wanfang, and Vendor Information Pages. Data were extracted from randomized controlled trials (RCTs) according to the selection criteria by 2 investigators independently. The quality of included trials was evaluated according to the Jadad scale standard. RESULTS: A total of 796 subjects from 19 different RCTs were included in this analysis. SCIT significantly reduced the asthma symptom scores (standardized mean difference of -0.94, 95% CI -1.58 to -0.29, P = .004) and the asthma medication scores (standardized mean difference of -1.06, 95% CI -1.70 to -0.42, P = .001) compared with the control group. However, there were no significant differences between subjects receiving SCIT and the control group in lung function (peak expiratory flow, percent-of-predicted FEV1, percent-of-predicted FVC) and specific antibody (allergen-specific immunoglobulin E) levels of blood serum (P > .05). In the studies containing data on safety, the incidences of systemic and local adverse reactions were 9.1% (8/88) and 17.2% (23/134), respectively, in subjects treated with SCIT, and no severe adverse events were reported. CONCLUSIONS: Our results suggest that SCIT is helpful in alleviating symptoms and reducing medication used in mite-sensitive asthma subjects, but with no improvement in lung function. The safety of SCIT is acceptable.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N